pteridines has been researched along with Multiple Sclerosis in 1 studies
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
Excerpt | Relevance | Reference |
---|---|---|
"Here, we generated mice with experimental autoimmune encephalomyelitis (EAE) and treated them with BI-D1870." | 1.43 | The ribosomal S6 kinase inhibitor BI-D1870 ameliorated experimental autoimmune encephalomyelitis in mice. ( Makishima, M; Takada, I; Yogiashi, Y, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Takada, I | 1 |
Yogiashi, Y | 1 |
Makishima, M | 1 |
1 other study available for pteridines and Multiple Sclerosis
Article | Year |
---|---|
The ribosomal S6 kinase inhibitor BI-D1870 ameliorated experimental autoimmune encephalomyelitis in mice.
Topics: Animals; Cell Movement; Central Nervous System; Disease Models, Animal; Encephalomyelitis, Autoimmun | 2016 |